Health

ANVISA keeps selling slimming sibutramine

05/28/2013

Body says that decision was made after a year of monitoring drug market
 
The Board decided to ANVISA, on Monday, keep selling medicines made from sibutramine substance as developed as antidepressant, but used in the treatment of obesity. According to ANVISA, the move comes after a year of monitoring drug market. The agency explains that this will keep monitoring the effects of it.
 
In 2011, ANVISA withdrew the three market appetite suppressants (femproporex, mazindol and amfepramone) and kept sibutramine, increasing restriction and promise of a reassessment of the measure this year. Thus, the rules for the use of sibutramine remain the same as those adopted in October of that year, when the agency issued a regulation that increased control over sibutramine.

On occasion, the Resolution 52/2011 ANVISA established the obligation of health professionals, companies holding registration and pharmacies to notify the National Sanitary Surveillance of cases of adverse effects related to the use of medicines containing sibutramine. It also indicated the discontinuation of the use of sibutramine in patients who do not get results after four weeks of product use.

The discussion of sibutramine began in 2010, when the study Scout with 10,744 obese 16 countries with cardiovascular disease and / or diabetes showed that the pill increased the risk of heart attack and stroke. Since then, ANVISA been restricting their use.

Read more about this topic in
© 1996-2013. All rights reserved Infoglobo Comunicação e Participações SA This material may not be published, broadcast, rewritten or redistributed without permission.


Source: The Globe - Online

Our news are taken in full from our partner sites. For this reason, we can not change the contents of the same even in cases of typos.

This article was translated by an automatic translation system, and was therefore not reviewed by people.